Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radioimmunotherapy as a targeted strategy of reduced-intensity conditioning for allogeneic transplantation in leukemia.

Frontiers in oncology·2026
Same author

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.

Leukemia & lymphoma·2026
Same author

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.

Transplantation and cellular therapy·2026
Same author

Case Report: donor cell-derived leukemia after allogeneic stem cell transplantation for metastatic renal cell carcinoma.

Frontiers in immunology·2026
Same author

[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.

Blood·2026
Same author

Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma.

Frontiers in oncology·2026

Related Experiment Video

Updated: Jun 14, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.

Aravind Ramakrishnan1, Brenda M Sandmaier

  • 1Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA. aramakri@fhcrc.org

Expert Review of Hematology
|April 13, 2010
PubMed
Summary

Myeloproliferative neoplasms (MPNs) are chronic stem cell disorders. Reduced-intensity conditioning regimens now make stem cell transplants a viable curative option for elderly MPN patients.

Keywords:
JAK-2bcr–ablgraft-versus-leukemiamyeloproliferative neoplasmreduced-intensity conditioningstem cell transplant

More Related Videos

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Related Experiment Videos

Last Updated: Jun 14, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by excess cell proliferation.
  • MPNs are chronic, potentially progressing to marrow failure or leukemia, primarily affecting the elderly.
  • Historically, supportive care was standard due to patient age and comorbidities limiting treatment options.

Purpose of the Study:

  • To review current strategies for using reduced-intensity conditioning (RIC) regimens in MPN treatment.
  • To discuss future directions for RIC regimens in managing MPNs.

Main Methods:

  • This is a review article summarizing existing literature and clinical practices.
  • Focuses on the application and outcomes of allogeneic hematopoietic cell transplantation with RIC in MPNs.

Main Results:

  • Allogeneic hematopoietic cell transplantation is the only curative treatment for MPNs.
  • RIC regimens have expanded eligibility for stem cell transplantation to elderly patients and those with comorbidities.
  • RIC allows safer administration of this life-saving therapy in previously ineligible patient groups.

Conclusions:

  • Reduced-intensity conditioning regimens represent a significant advancement in treating myeloproliferative neoplasms.
  • These regimens broaden the applicability of curative stem cell transplantation for MPN patients, including the elderly.
  • Further research and strategic implementation of RIC are crucial for optimizing outcomes in MPN management.